DME Capital Management David Einhorn
New York, NY 21 processed 13Fs on this site, 2021 Q3 to 2026 Q3
- $3.6B
- 45 holdings
- 2026 Q3
- −9.1% QoQ
- Top 5 37.4%
AUM over time
Book
| GRBK, Green Brick Partners | Hold | 9,467,383 | $62.88 | $595M | — | — | |
| FLR, Fluor | New | 3,819,580 | $51.27 | $196M | +3,819,580 | +$196M | |
| CNR, Core Natural Resources | Reduce −2.4% | 2,155,640 | $69.74 | $150M | −53,000 | −$20M | |
| BHF, Brighthouse Financial | Reduce −1.5% | 2,760,097 | $53.77 | $148M | −41,000 | −$14M | |
| KD, Kyndryl | Reduce −19.9% | 3,311,297 | $41.96 | $139M | −823,910 | +$9.1M | |
| PENN, Penn Entertainment | Add +19.6% | 7,494,440 | $17.87 | $134M | +1,226,000 | +$32M | |
| CNH, CNH Industrial | Reduce −2.5% | 7,872,610 | $12.96 | $102M | −203,930 | +$2.8M | |
| PKG, Graphic Packaging | Add +349.4% | 4,705,950 | $21.07 | $99M | +3,658,850 | +$72M | |
| DHT, DHT Holdings | Add +15.3% | 7,620,934 | $10.81 | $82M | +1,010,000 | +$13M | |
| TECK, Teck Resources | Hold | 2,000,000 | $40.38 | $81M | — | — | |
| HPQ, HP | Hold | 3,018,770 | $24.46 | $74M | — | — | |
| TEVA, Teva Pharmaceutical Industries | Add +565.0% | 3,778,777 | $16.76 | $63M | +3,210,577 | +$55M | |
| CPRI, Capri | Hold | 3,479,107 | $17.70 | $62M | — | — | |
| LBTYA, Liberty Global | Hold | 5,220,502 | $10.01 | $52M | — | — | |
| GLD, SPDR Gold Shares | Reduce −6.0% | 169,411 | $304.83 | $52M | −10,740 | −$267K | |
| ROIV, Roivant Sciences | Reduce −16.4% | 4,551,057 | $11.27 | $51M | −890,110 | −$3.6M | |
| WFRD, Weatherford International | Add +110.4% | 960,810 | $50.31 | $48M | +504,171 | +$24M | |
| CNC, Centene | Add +53.3% | 839,170 | $54.28 | $46M | +291,600 | +$12M | |
| SDRL, Seadrill | Hold | 1,588,828 | $26.25 | $42M | — | — | |
| CI, Cigna | New | 93,750 | $330.58 | $31M | +93,750 | +$31M | |
| ACHC | Add +615.7% | 865,011 | $22.69 | $20M | +744,151 | +$16M | |
| VSXY, Victorias Secret And | New | 887,750 | $18.52 | $16M | +887,750 | +$16M | |
| LKFT, Galapagos | Hold | 482,746 | $27.99 | $14M | — | — | |
| COYA, Coya Therapeutics | Hold | 1,646,440 | $5.75 | $9.5M | — | — | |
| SNX, TD Synnex | Reduce −28.0% | 33,270 | $135.70 | $4.5M | −12,945 | −$290K | |
| GDX, Vaneck ETF Trust | Hold | 76,460 | $52.06 | $4M | — | — | |
| OIH, Vaneck ETF Trust | Add +29.0% | 15,940 | $230.29 | $3.7M | +3,580 | +$431K | |
| SHC, Sotera Health | New | 233,690 | $11.12 | $2.6M | +233,690 | +$2.6M | |
| GPRO, Gopro | Hold | 2,823,100 | $0.7573 | $2.1M | — | — | |
| PTON, Peloton Interactive | Reduce −96.4% | 179,470 | $6.94 | $1.2M | −4,823,938 | −$30M | |
| GANX, Gain Therapeutics | Hold | 566,130 | $1.80 | $1M | — | — | |
| NUVB, Nuvation Bio | Hold | 34,995 | $1.95 | $68K | — | — |
Exits / last held
Gone since 2025 Q1, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| VTRS, Viatris | Exit | 0 | $8.71 | $52M | −6,000,830 | −$52M | |
| DLTR, Dollar Tree | Exit | 0 | $75.07 | $33M | −436,360 | −$33M | |
| ALIT, Alight | Exit | 0 | $5.93 | $5.9M | −1,000,000 | −$5.9M |
Filings history
21 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q3 | 45 | $3.6B | −9.1% | 13F-HR | 11/16/2026 | 000117266126005372 |
| 2026 Q2 | 46 | $3.9B | +22.5% | 13F-HR | 8/14/2026 | 000117266126003786 |
| 2026 Q1 | 45 | $3.2B | +12.0% | 13F-HR | 5/15/2026 | 000117266126002341 |
| 2025 Q4 | 41 | $2.8B | +12.1% | 13F-HR | 2/17/2026 | 000117266126001122 |
| 2025 Q3 | 37 | $2.5B | +9.3% | 13F-HR | 11/14/2025 | 000117266125005032 |
| 2025 Q2 | 34 | $2.3B | +17.8% | 13F-HR | 8/14/2025 | 000117266125003351 |
| 2025 Q1 | 33 | $2B | +1.5% | 13F-HR | 5/15/2025 | 000117266125002307 |
| 2024 Q4 | 36 | $1.9B | −19.1% | 13F-HR | 2/14/2025 | 000117266125001165 |
| 2024 Q3 | 38 | $2.4B | +17.6% | 13F-HR | 11/14/2024 | 000117266124005240 |
| 2024 Q2 | 39 | $2B | −6.5% | 13F-HR | 8/14/2024 | 000117266124003549 |
| 2024 Q1 | 42 | $2.2B | — | 13F-HR | 5/15/2024 | 000117266124002489 |
| 2023 Q4 | 40 | $2B | +16.3% | 13F-HR | 2/14/2024 | 000117266124001512 |
| 2023 Q3 | 39 | $1.8B | −17.4% | 13F-HR | 11/14/2023 | 000117266123004012 |
| 2023 Q2 | 41 | $2.1B | +15.9% | 13F-HR | 8/14/2023 | 000117266123003174 |
| 2023 Q1 | 39 | $1.8B | +27.4% | 13F-HR | 5/15/2023 | 000117266123002282 |
| 2022 Q4 | 42 | $1.4B | +2.3% | 13F-HR | 2/14/2023 | 000117266123001336 |
| 2022 Q3 | 42 | $1.4B | +9.8% | 13F-HR | 11/14/2022 | 000117266122002565 |
| 2022 Q2 | 47 | $1.3B | −18.3% | 13F-HR | 8/15/2022 | 000117266122002019 |
| 2022 Q1 | 52 | $1.6B | −10.0% | 13F-HR | 5/16/2022 | 000117266122001474 |
| 2021 Q4 | 57 | $1.7B | +17.2% | 13F-HR | 2/14/2022 | 000117266122000884 |
| 2021 Q3 | 58 | $1.5B | — | 13F-HR | 11/15/2021 | 000117266121002370 |
About
DME Capital Management
21 processed 13Fs on this site, 2021 Q3 to 2026 Q3
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
- One Up On Wall Street (Lynch), Peter Lynch View on Amazon